ZURA BIO LIMITED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.755 USD | +0.96% |
|
+8.03% | +0.86% |
| 05:20pm | Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating | MT |
| 09/05 | Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 287M 23.95B |
|---|---|---|---|---|---|
| Net income 2024 * | -48M -4.01B | Net income 2025 * | -62M -5.18B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-4.99
x | P/E ratio 2025 * |
-4.47
x | Employees | 15 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.06% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.53% | ||
| 1 week | +8.03% | ||
| Current month | +10.30% | ||
| 1 month | +70.04% | ||
| 3 months | +17.75% | ||
| 6 months | +10.30% | ||
| Current year | +0.86% |
1 week
4.50
4.88
1 month
2.704.95
Current year
2.004.95
1 year
2.0014.00
3 years
2.0037.55
5 years
2.0037.55
10 years
2.0037.55
| Managers | Title | Age | Since |
|---|---|---|---|
Someit Sidhu
FOU | Founder | 34 | 18/22/18 |
Robert Lisicki
CEO | Chief Executive Officer | 57 | 08/01 |
Verender Badial
DFI | Director of Finance/CFO | 51 | 01/23/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Amit Munshi
CHM | Chairman | 56 | 01/23/01 |
Steven Schoch
BRD | Director/Board Member | 64 | 01/23/01 |
Sandeep Kulkarni
BRD | Director/Board Member | 43 | 01/22/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.67% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/24/08 | 4.71 | +1.51% | 93 882 |
| 09/24/09 | 4.6 | -2.34% | 101,720 |
| 08/24/08 | 4.71 | +1.51% | 93,882 |
| 07/24/07 | 4.64 | -1.07% | 72,890 |
| 06/24/06 | 4.69 | +1.52% | 137,068 |
End-of-day quote Nasdaq, May 08, 2024
More quotes
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Calendar
12/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.6
USD
Average target price
18
USD
Spread / Average Target
+291.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.86% | 287M | |
| +3.19% | 108B | |
| +11.10% | 104B | |
| +1.28% | 22.33B | |
| -12.75% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -9.75% | 17.64B | |
| +4.20% | 14.05B | |
| +34.79% | 12.51B |
- Stock Market
- Equities
- ZURA Stock